Insider · CIK 0001826323

Thorell Marella

Reports to the SEC for 6 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001826323

Forms 4 and 5

Insider transactions

36 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-08	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+7,500 sh	—	—	7,500
2026-03-04	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+22.5K sh	—	—	22,500
2025-10-09	EPIXESSA Pharma Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−2,881 sh	—	—	0
2025-02-07	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+650K sh	—	—	650,000
2024-07-01	CARMCarisma Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+38.7K sh	—	—	38,700
2024-03-25	EPIXESSA Pharma Inc. · OptionsA Award	Director	AAward	+50K sh	—	—	50,000
2024-03-25	MCRBSeres Therapeutics, Inc. · Stock Options (right to buy)A Award	See Remarks	AAward	+700K sh	—	—	700,000
2023-11-08	Evelo Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−1,811 sh	$0.33	−$597.63	22,259
2023-11-07	Evelo Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,500 sh	—	—	24,070
2023-11-07	Evelo Biosciences, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,500 sh	—	—	6,500
2023-11-02	Evelo Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−3,999 sh	$0.33	−$1,319.67	17,570
2023-11-01	Evelo Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12.5K sh	—	—	21,569
2023-11-01	Evelo Biosciences, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12.5K sh	—	—	25,000
2023-09-11	Evelo Biosciences, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+37.5K sh	—	—	37,500
2023-08-08	Evelo Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−2,004 sh	$9.51	−$19.1K	9,069
2023-08-07	Evelo Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,500 sh	—	—	11,073
2023-08-07	Evelo Biosciences, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,500 sh	—	—	13,000
2023-05-08	Evelo Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−38.5K sh	$0.13	−$4,835.641	91,469
2023-05-07	Evelo Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+130K sh	—	—	130,000
2023-05-07	Evelo Biosciences, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−130K sh	—	—	390,000
2023-02-07	Evelo Biosciences, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+520K sh	—	—	520,000
2022-12-13	GRIGRI Bio, Inc.J Other	Director	JOther	−28.5K sh	—	—	9,506
2022-09-01	Evelo Biosciences, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+440K sh	—	—	440,000
2022-07-01	GRIGRI Bio, Inc.A Award	Director	AAward	+38K sh	—	—	38,023
2022-06-29	EPIXESSA Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2022-06-09	GRIGRI Bio, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2022-03-21	Centessa Pharmaceuticals plcJ Other	Chief Accounting Officer	JOther	+52.1K sh	—	—	53,101
2022-02-01	Centessa Pharmaceuticals plcShare Option (right to buy)A Award	Chief Accounting Officer	AAward	+67.5K sh	—	—	67,500
2021-06-02	Centessa Pharmaceuticals plcP Purchase	Chief Accounting Officer	PPurchase	+1,000 sh	$20.00	+$20K	1,000
2021-05-27	Centessa Pharmaceuticals plcShare Option (right to buy)A Award	Chief Accounting Officer	AAward	+138K sh	—	—	137,500
2021-02-19	Centessa Pharmaceuticals plcShare Option (right to buy)A Award	Chief Accounting Officer	AAward	+208K sh	—	—	208,474
2021-02-12	GRIGRI Bio, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2021-01-29	Centessa Pharmaceuticals plcShare Option (right to buy)A Award	Chief Accounting Officer	AAward	+59K sh	—	—	58,956
2021-01-29	Centessa Pharmaceuticals plcShare Option (right to buy)A Award	Chief Accounting Officer	AAward	+9,487 sh	—	—	9,487
2020-12-11	EPIXESSA Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2020-12-11	EPIXESSA Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,500

Recent filings

Accepted (ET)
Jul 104
Thorell Marella0001193125-26-300922
SEC(opens sec.gov)
Mar 64
Thorell Marella0001193125-26-096692
SEC(opens sec.gov)
Oct 154
Thorell Marella0001104659-25-099644
SEC(opens sec.gov)
Feb 114
Thorell Marella0000950170-25-017916
SEC(opens sec.gov)
Jul 14
Thorell Marella0001104659-24-076988
SEC(opens sec.gov)
Mar 284
Thorell Marella0000950172-24-000140
SEC(opens sec.gov)
Mar 274
Thorell Marella0000950170-24-037213
SEC(opens sec.gov)
Nov 84
Thorell Marella0001694665-23-000175
SEC(opens sec.gov)
Nov 34
Thorell Marella0001694665-23-000167
SEC(opens sec.gov)
Sep 134
Thorell Marella0001694665-23-000155
SEC(opens sec.gov)
Aug 94
Thorell Marella0001694665-23-000133
SEC(opens sec.gov)
May 104
Thorell Marella0001694665-23-000052
SEC(opens sec.gov)
May 94
Thorell Marella0001694665-23-000044
SEC(opens sec.gov)

Companies

Address

C/O SERES THERAPEUTICS, INC. 101 CAMBRIDGE PARK DRIVE

CAMBRIDGE, MA, 02140